Neoadjuvant Nivolumab/Ipilimumab for Oral Cavity SCC: Jonathan Schoenfeld, MD, MPH

Due to intensive treatments, severe side effects, and a high rate of recurrence, oral cavity squamous cell carcinoma (SCC) is a challenging disease associated with poor outcomes. According to a recent study, neoadjuvant nivolumab alone or in combination with ipilimumab may be a safe and effective treatment for patients with oral cavity SCC undergoing surgical resection. In this interview, Jonathan Schoenfeld, MD, MPH, Associate Professor of Radiation Oncology at Harvard Medical School and first ...
Continue reading

How Cancer Type Affects COVID-19 Outcomes: Lennard Lee, DPhil, MRCP, BMBCh

While patients with cancer are at an increased risk of experiencing poor outcomes from COVID-19, there is significant variability in COVID-19 risk and mortality among patients with different tumor types and demographics such as age and sex, with those with hematologic malignancies facing the highest risk. In this interview with i3 Health, Lennard Lee, DPhil, MRCP, BMBCh, an Honorary Research Fellow at the University of Birmingham's Institute of Cancer and Genomic Sciences, discusses the signific...
Continue reading

Vivek Subbiah, MD, on Dabrafenib/Trametinib Efficacy in Biliary Tract Cancer

According to a recent study, led by Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, dabrafenib in combination with trametinib is an effective treatment option for patients with BRAFV600E -mutated biliary tract cancer (BTC). In an interview with i3 Health, Dr. Subbiah shares insights on the significance of these study results and unmet needs and future treatment in this patient population. What are the most challenging aspects of treating patients with BRAFV600E -mutated ...
Continue reading

Geriatric and Surgical Comanagement for Older Patients With Cancer: Armin Shahrokni, MD, MPH

Patients aged 75 years and older face an increased risk of mortality and postoperative events when undergoing surgical treatment for cancer. In a study recently published in JAMA Network Open, a research team led by first author Armin Shahrokni, MD, MPH, found that patients whose care was managed by both the surgical and geriatric teams experienced significantly better outcomes compared with those whose care was provided by the surgical team alone. In this interview with i3 Health, Dr. Shahrokni...
Continue reading

Hans C. Lee, MD: FDA Approval of Belantamab Mafodotin-blmf for R/R Multiple Myeloma

For patients with relapsed or refractory (R/R) multiple myeloma (MM), a new treatment has just been recently FDA approved: belantamab mafodotin-blmf (BLENREP®, GlaxoSmithKline). In an interview with i3 Health, Hans C. Lee, MD, of The University of Texas MD Anderson Cancer Center, speaks about the significance of this approval and what the future may look like on treating these patients. What are the most challenging aspects of treating patients with R/R MM? Hans C. Lee, MD: While there have been...
Continue reading

Tafasitamab/Lenalidomide for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Gilles Salles, MD, PhD

Recently, the FDA granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. In this interview with i3 Health, Gilles Salles, MD, PhD, principal investigator of the phase 2 L-MIND trial, on which the approval was based, discusses the significance of the approval, adverse events of note with tafasitamab/lenal...
Continue reading

Atezolizumab Triplet Therapy for BRAF V600-Mutant Melanoma: Paolo A. Ascierto, MD

Recently, the FDA approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) and cobimetinib (Cotellic®, Genentech) for the treatment of BRAF V600-mutant advanced melanoma. In this interview with i3 Health, Paolo A. Ascierto, MD, principal investigator of the IMspire150 trial, on which the approval was based, discusses the approval's significance and the most promising research developments in the treatment of BRAF...
Continue reading

​Connecting With Patients With Cancer in Spite of COVID-19: Kiri A. Cook, MD

The stress of having cancer and the physical and financial toll of treatment can be difficult for patients, even under normal circumstances. During the COVID-19 pandemic, patients face additional stressors, including not only the fear of mortality from COVID-19 but also the emotional impact of isolation. This sense of isolation can be present even in patients' cancer care, as many appointments take place through videoconferencing and telephone calls; even when in-person appointmen...
Continue reading

IVC Filter Efficacy in Patients With Cancer and Deep Vein Thrombosis: Rahul A. Sheth, MD

Patients with cancer are at substantially increased risk for deep vein thrombosis (DVT) and resulting pulmonary embolism. Together, these two forms of venous thromboembolism constitute the second leading cause of death for patients with known malignancies. The standard of care for DVT is anticoagulation, yet many patients with cancer and DVT are unable to receive anticoagulation because of the bleeding risk that it poses. In a study recently published in JAMA Internal Medicine, a team of investi...
Continue reading

Cancer Overscreening in Older Adults: Jennifer L. Moss, PhD

According to a study recently published in JAMA Network Open, a high proportion of older adults with average cancer risk are overscreened for colorectal, cervical, and breast cancers after surpassing specified upper age limits recommended by the US Preventive Services Task Force (USPSTF). In this interview, Jennifer L. Moss, PhD, first author of the study, discusses the significance of these findings, explains the risks of overscreening, and shares advice for reducing overscreening among older a...
Continue reading

Oral Decitabine/Cedazuridine for MDS: Olatoyosi Odenike, MD

In this interview, Olatoyosi Odenike, MD, speaks with i3 Health about the approval of oral decitabine/cedazuridine (Inqovi®, Astex Pharmaceuticals, Inc.) for adult patients with myelodysplastic syndromes (MDS). Dr. Odenike, Director of the Leukemia Program at the University of Chicago and an investigator of one of the clinical trials on which the approval was based, discusses the challenges of treating patients with MDS and the significance of the approval of oral decitabine/cedazuridine. What a...
Continue reading

Breast Cancer Chemotherapy in Older Patients With Comorbidities: Nina Tamirisa, MD

Many older patients with breast cancer have significant comorbidities, increasing the challenges of treatment. These challenges are compounded by the fact that elderly patients with multiple comorbidities are frequently excluded from participating in clinical trials, resulting in a lack of treatment data for this population. Nina Tamirisa, MD, and colleagues recently published a study in JAMA Oncology reporting that in older patients with multiple comorbidities and estrogen receptor–positive, no...
Continue reading

Lurbinectedin for Small-Cell Lung Cancer: Luis Paz-Ares, MD

Last month, the FDA granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer experiencing disease progression on or after platinum-based chemotherapy. In this interview, Luis Paz-Ares, MD, principal investigator of the phase 2 basket trial PM1183-B-005-14 (Study B-005; NCT02454972), on which the approval was based, spoke with i3 Health about the approval's significance, notable adverse events with lurbinectedin, and the wealth...
Continue reading

Murray Brunt, MBBS on 10-Year Results of FAST: 5-Fraction RT for Breast Cancer

Ten-year results from the FAST study show that there are no significant differences in normal tissue effects (NTE) rates after 28.5 Gy/5 fractions (fr) compared with 50 Gy/25 fr in patients with early breast cancer; however, NTE were higher with 30 Gy/5 fr, according to a study published in the Journal of Clinical Oncology. In an interview with i3 Health, Murray Brunt, MBBS, FRCP, FRCR, lead study author, provides insights on the significance of these results and how treatment will evolve in the...
Continue reading

John Leonard, MD: FDA Approval of Selinexor for DLBCL

Selinexor (Xpovio®, Karyopharm Therapeutics) was recently FDA approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This approval extends to patients with DLBCL that resulted from follicular lymphoma and those who had previously received at least two prior lines of systemic therapy. John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine, discussed with i3 Health the importance of this approval and the fu...
Continue reading

Hypertensive Medications and Reduced Colorectal Cancer Risk: Wai K. Leung, MD

In this interview, Wai K. Leung, MD, speaks with i3 Health about his research team's finding, recently published in Hypertension, that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with a decreased risk of colorectal cancer within three years of colonoscopy. Dr. Leung discusses the significance of the study's results and shares potential reasons behind the link between ACE inhibitor and ARB use and reduced colorectal cancer risk. Can you c...
Continue reading

Avelumab for Urothelial Carcinoma: An Interview With Thomas Powles, MBBS, MRCP, MD

The FDA recently approved avelumab (Bavencio®, EMD Serono, Inc.) for patients with advanced urothelial carcinoma (UC). Thomas Powles, MBBS, MRCP, MD, discusses with i3 Health the implication of this approval and future steps for research and offers community oncologists advice on treating this patient population. What are the most challenging aspects of treating patients with locally advanced or metastatic UC? Thomas Powles, MBBS, MRCP, MD: The overall survival outcomes are poor for the disease....
Continue reading

The Changing Standards for FDA Oncology Approvals: Talal Hilal, MD

The FDA approval process is in place to ensure that drugs are safe and effective before they are made available to the public. But do the clinical trials that lead to approval truly ascertain whether a drug is efficacious? Fully two-thirds of anticancer drug clinical trials leading to FDA approvals between 2014 and 2019 had at least one important limitation in trial design: lack of randomization, lack of significant overall survival advantage, inappropriate use of crossover, and/or use of a...
Continue reading

Successfully Treating Kaposi Sarcoma: Robert Yarchoan, MD

Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI), recently spoke with i3 Health about the approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV. In this second installment of his interview, Dr. Yarchoan shares valuable advice with oncologists as they seek to enhance outcomes and treatment experiences for patients with Kaposi sarcoma. What advice can you share with oncologists treating patients with...
Continue reading

Burosumab-twza for Tumor-Induced Osteomalacia: Suzanne Jan de Beur, MD

In this interview with i3 Health, Suzanne Jan de Beur, MD, discusses the recent approval of burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), for patients with tumor-induced osteomalacia (TIO) whose tumors are unable to be localized or resected. Dr. Jan de Beur, lead investigator of one of the phase 2 clinical trials on which the approval was based, explains the challenges involved in diagnosing and treating TIO and discusses the significance of the approval of burosumab-twza for pati...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.